Skip to content
Storytelling Co – Lifestyle
Author:
Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
June 2, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2026
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 8, 2026
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
May 4, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 27, 2026
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
March 25, 2026